Kodiak Sciences Inc. — Form SCHEDULE 13D/A
Filed September 30, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 52/100
What the filing says
On 9/28–9/29/2026, Baker Brothers Life Sciences, L.P. and 667, L.P. purchased approximately 730,000 combined shares of Kodiak Sciences at prices ranging from $60.50 to $85.95 per share, increasing their combined holdings to 21.86 million shares (34.8% of the class). Baker Brothers holds 20.19 million shares (32.1%); 667, L.P. holds 1.67 million shares (2.7%). The purchases appear to be open-market transactions executed across many discrete tranches.
Why this rating
Open-market accumulation by existing major holders (~$60–63M invested) represents ~49% of company's $121.6M market cap—material absolute size but routine insider buying by known shareholders with no control-change trigger or strategic announcement.
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.